Annacarmen Petrizzo

Dr. Annacarmen Petrizzo


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
Luigi BuonaguroLuigi Buonaguro
Luigi Buonaguro
APAnnacarmen Petrizzo
Annacarmen Petrizzo
Maria Lina TorneselloMaria Lina Tornesello
Maria Lina Tornesello
Franco M BuonaguroFranco M Buonaguro
Franco M Buonaguro
Vaccines represent a strategic successful tool used to prevent or contain diseases with high morbidity and/or mortality. However, while vaccines have proven to be effective in combating pathogenic microorganisms, based on the immune recognition of these foreign antigens, vaccines aimed at inducing effective antitumor activity are still unsatisfactory. Nevertheless, the effectiveness of the two licensed cancer-preventive vaccines targeting tumor-associated viral agents (anti-HBV [hepatitis B virus], to prevent HBV-associated hepatocellular carcinoma, and anti-HPV [human papillomavirus], to prevent HPV-associated cervical carcinoma), along with the recent FDA approval of sipuleucel-T (for the therapeutic treatment of prostate cancer), represents a significant advancement in the field of cancer vaccines and a boost for new studies in the field. Specific active immunotherapies based on anticancer vaccines represent, indeed, a field in continuous evolution and expansion. Significant improvements may result from the selection of the appropriate tumor-specific target antigen (to overcome the peripheral immune tolerance) and/or the development of immunization strategies effective at inducing a protective immune response. This review aims to describe the vast spectrum of tumor antigens and strategies to develop cancer vaccines.

31 October 2014 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
MTMaria Tagliamonte
Maria Tagliamonte
APAnnacarmen Petrizzo
Annacarmen Petrizzo
Maria Lina TorneselloMaria Lina Tornesello
Maria Lina Tornesello
Franco M BuonaguroFranco M Buonaguro
Franco M Buonaguro
Luigi BuonaguroLuigi Buonaguro
Luigi Buonaguro
Vaccines targeting pathogens are generally effective and protective because based on foreign non-self antigens which are extremely potent in eliciting an immune response. On the contrary, efficacy of therapeutic cancer vaccines is still disappointing. One of the major reasons for such poor outcome, among others, is the difficulty of identifying tumor-specific target antigens which should be unique to the tumors or, at least, overexpressed on the tumors as compared to normal cells. Indeed, this is the only option to overcome the peripheral immune tolerance and elicit a non toxic immune response. New and more potent strategies are now available to identify specific tumor-associated antigens for development of cancer vaccine approaches aiming at eliciting targeted anti-tumor cellular responses. In the last years this aspect has been addressed and many therapeutic vaccination strategies based on either whole tumor cells or specific antigens have been and are being currently evaluated in clinical trials. This ...

1 October 2013 in Journal of Hepatology
Verified
Journal Article
Open access
Luigi BuonaguroLuigi Buonaguro
Luigi Buonaguro
APAnnacarmen Petrizzo
Annacarmen Petrizzo
MTMaria Tagliamonte
Maria Tagliamonte
Maria Lina TorneselloMaria Lina Tornesello
Maria Lina Tornesello
Franco M BuonaguroFranco M Buonaguro
Franco M Buonaguro
Hepatocellular carcinoma (HCC) is the most common liver malignancy, representing the third and fifth leading cause of death from cancer worldwide in men and women, respectively. The main risk factor for the development of HCC is the hepatitis B and C virus (HBV and HCV) infection; non-viral causes (e.g., alcoholism and aflatoxin) are additional risk factors. HCC prognosis is generally poor because of the low effectiveness of available treatments and the overall 5-year survival rate is approximately 5-6%. In this framework, immunotherapeutic interventions, including cancer vaccines, may represent a novel and effective therapeutic tool. However, only few immunotherapy trials for HCC have been conducted so far with contrasting results, suggesting that improvements in several aspects of the immunotherapy approaches need to be implemented. In particular, identification of novel specific tumor antigens and evaluation of most advanced combinatorial strategies could result in unprecedented clinical outcomes with great beneficial effect for HCC patients. The state of the art in immunotherapy strategies for HCC and future perspectives are reported in the present review.

1 March 2019 in Annals of Hepatology
Verified
Journal Article
Open access
LBLuigi Buonaguro
Luigi Buonaguro
AMAngela Mauriello
Angela Mauriello
BCBeatrice Cavalluzzo
Beatrice Cavalluzzo
APAnnacarmen Petrizzo
Annacarmen Petrizzo
MTMaria Tagliamonte
Maria Tagliamonte
Hepatocellular carcinoma (HCC) is considered an immunogenic tumor that arises in chronically inflamed livers due to underlying chronic liver disease caused by viral and non-viral pathogenesis. This inflammation leads to tumor development and is associated to higher tumor immunogenicity. For this reason immunotherapeutic approaches may be suitable therapeutic strategies for HCC. Indeed, several preclinical and clinical data support this hypothesis showing that immunotherapy and even more their combination may be a good alternative candidate for the treatment of HCC patients. However, considering that the liver plays a central role in host defense as well as in the maintenance of self-tolerance, it is characterized by a strong intrinsic immune suppressive microenvironment as well as by a high immune evasion, which may represent a major impediment for an effective immune response against tumor. Furthermore, the low expression of tumor antigens on liver cancer cells leads to a lower T-cell activation and tumor infiltration, resulting in a less efficient control of the tumor growth and, consequently, in a worse clinical outcome. For this reason, strategies should be developed to counteract the different factors in the HCC tumor microenvironment playing a major role in reducing the effects of immunotherapy.

1 April 2016 in Current Opinion in Immunology
Verified
Journal Article
Closed access
MTMaria Tagliamonte
Maria Tagliamonte
APAnnacarmen Petrizzo
Annacarmen Petrizzo
Maria Lina TorneselloMaria Lina Tornesello
Maria Lina Tornesello
Gennaro CilibertoGennaro Ciliberto
Gennaro Ciliberto
Franco M BuonaguroFranco M Buonaguro
Franco M Buonaguro
Luigi BuonaguroLuigi Buonaguro
Luigi Buonaguro

20 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
AMAngela Mauriello
Angela Mauriello
RZRoberta Zeuli
Roberta Zeuli
BCBEATRICE CAVALLUZZO
BEATRICE CAVALLUZZO
APAnnacarmen Petrizzo
Annacarmen Petrizzo
Maria Lina TorneselloMaria Lina Tornesello
Maria Lina Tornesello
Luigi BuonaguroLuigi Buonaguro
Luigi Buonaguro
Cancer genome instability leads to accumulation of mutations which may result into tumor-specific mutated “neoantigens”, not be affected by central T-cell tolerance. Such neoantigens are considered the optimal target for the patient’s anti-tumor T cell immunity as well as for personalized cancer immunotherapy strategies. However, only a minor fraction of predicted neoantigens are relevant to the clinical outcome. In the present study, a prediction algorithm was applied using datasets of RNA sequencing from all 377 Hepatocellular carcinoma (HCC) patients available at The Cancer Genome Atlas (TCGA), to predict neoantigens to be presented by each patient’s autologous HLA molecules. Correlation with patients’ survival was performed on the 115 samples for whom the exact date of death was known. A total of 30 samples were used for the training set, and 85 samples were used for the validation sets. Neither the somatic mutations nor the number nor the quality of the predicted neoantigens correlate as single parameter with survival of HCC patients who do not undergo immunotherapy treatment. Furthermore, the preferential presentation of such neoantigens in the context of one of the major histocompatibility complex MHC class I molecules does not have an impact on the survival. On the contrary, the expression of Granzyme A (GZMA) is significantly correlated with survival and, in the context of high GZMA, a direct correlation between number and quality of neoantigens with survival is observed. This is in striking contrast to results described in cancer patients undergoing immunotherapy, in which a strong correlation between Tumor Mutational Burden (TMB), number of predicted neoantigens and survival has been reported.